Journal
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
Volume 12, Issue 1, Pages 194-203Publisher
SPRINGER
DOI: 10.1007/s11481-016-9722-5
Keywords
Immunotherapy; Alzheimer's disease; Amyloid-beta; Meta-analysis, ARIA
Categories
Funding
- University of Sydney
Ask authors/readers for more resources
Immunotherapeutics targeting amyloid-beta (A beta) have had mixed results in clinical trials. The present study aims to evaluate the safety and clinical efficacy of immunotherapeutic agents targeting A beta in Alzheimer's disease. Randomised controlled trials of at least two weeks duration were included in the review. Fourteen randomised controlled trials (n = 5554) were identified in a systematic search of eight electronic databases. Upon pooling of data, there was no increased risk of any adverse event, serious adverse events, or death with the exception of a near fivefold increase in amyloid-related imaging abnormalities (ARIA; OR 4.79, 95% CI 1.24-18.55; p = 0.02). Of the cognitive indicators, the Mini-Mental State Examination (MMSE) showed a small statistically significant improvement (diff in means =0.44; p = 0.02), while the others (ADAS-cog, ADCS-ADL, and CDR-sb) showed no change. Therefore, immunotherapeutic agents have been relatively well tolerated, with some promise for cognitive improvements if the occurrence of ARIA can be mitigated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available